{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T22:09:26Z","timestamp":1758924566083},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"S3","license":[{"start":{"date-parts":[[2011,2,20]],"date-time":"2011-02-20T00:00:00Z","timestamp":1298160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Anemia is frequently seen in patients with chronic kidney disease and also in those with cancer. There are factors in the pathogenesis of anemia that are common to both clinical conditions, with iron insufficiency, inflammation, and upregulation of hepcidin activity playing a part in both chronic disease states. Diagnostic laboratory markers for detecting functional iron deficiency in renal disease and oncology are not ideal, and the most widely available tests, such as serum ferritin and transferrin saturation, have poor sensitivity and specificity. Other tests incorporating a surrogate for iron sufficiency in the RBC and reticulocyte (such as percentage hypochromic RBCs or reticulocyte hemoglobin content) have greater sensitivity\/specificity, but unfortunately these tests are not widely available in many hospital laboratories. Iron supplementation may be given via the oral route, i.m., or i.v., but it is now clear that, in both the nephrology and oncology settings, i.v. iron is superior to oral iron in terms of efficacy. Oral iron is associated with a high incidence of gastrointestinal side effects, and although large epidemiological studies of i.v. iron are reassuring, the long-term safety of parenteral iron is not established in well-designed adequately powered randomized controlled trials.<\/jats:p>","DOI":"10.1634\/theoncologist.2011-s3-25","type":"journal-article","created":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T19:43:36Z","timestamp":1316461416000},"page":"25-34","source":"Crossref","is-referenced-by-count":24,"title":["Iron Supplementation in Nephrology and Oncology: What Do We Have in Common?"],"prefix":"10.1093","volume":"16","author":[{"given":"Iain C.","family":"Macdougall","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, King's College Hospital, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,2,20]]},"reference":[{"issue":"suppl 8","key":"2021122304263243300_B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0093-7754(01)90205-2","article-title":"Biological basis of anemia","volume":"28","author":"Bron","year":"2001","journal-title":"Semin Oncol"},{"key":"2021122304263243300_B2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122304263243300_B3","first-page":"449","article-title":"Erythropoietin levels in uremic nephric and anephric patients","volume":"93","author":"Caro","year":"1979","journal-title":"J Lab Clin Med"},{"issue":"suppl 7","key":"2021122304263243300_B4","first-page":"2","article-title":"Anemia in cancer patients","volume":"25","author":"Ludwig","year":"1998","journal-title":"Semin Oncol"},{"key":"2021122304263243300_B5","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/djp387","article-title":"Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer","volume":"101","author":"Hershman","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2021122304263243300_B6","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J Clin Invest"},{"key":"2021122304263243300_B7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0014-5793(00)01920-7","article-title":"LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity","volume":"480","author":"Krause","year":"2000","journal-title":"FEBS Lett"},{"key":"2021122304263243300_B8","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1074\/jbc.M008922200","article-title":"Hepcidin, a urinary antimicrobial peptide synthesized in the liver","volume":"276","author":"Park","year":"2001","journal-title":"J Biol Chem"},{"key":"2021122304263243300_B9","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1074\/jbc.M008923200","article-title":"A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload","volume":"276","author":"Pigeon","year":"2001","journal-title":"J Biol Chem"},{"key":"2021122304263243300_B10","doi-asserted-by":"crossref","first-page":"8780","DOI":"10.1073\/pnas.151179498","article-title":"Lack of hepcidin gene expression and severe tissue iron overload in upstream factor 2 (USF2) knockout mice","volume":"98","author":"Nicolas","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122304263243300_B11","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"2021122304263243300_B12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.ajkd.2009.12.030","article-title":"Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD","volume":"55","author":"Babitt","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2021122304263243300_B13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0305-0491(84)90292-X","article-title":"The activity of tissue enzymes in iron-deficient rat and man: An overview","volume":"77","author":"Galan","year":"1984","journal-title":"Comp Biochem Physiol B"},{"key":"2021122304263243300_B14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/apa.1989.78.s361.71","article-title":"Iron deficiency and the brain","volume":"361","author":"Parks","year":"1989","journal-title":"Acta Paediatr Scand Suppl"},{"key":"2021122304263243300_B15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/apa.1989.78.s361.63","article-title":"Biochemical effects of iron deprivation","volume":"361","author":"Hercberg","year":"1989","journal-title":"Acta Paediatr Scand Suppl"},{"key":"2021122304263243300_B16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF02829934","article-title":"A precious metal: Iron, an essential nutrient for all cells","volume":"1","author":"Cairo","year":"2006","journal-title":"Genes Nutr"},{"key":"2021122304263243300_B17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1053\/j.gastro.2010.06.013","article-title":"Hereditary hemochromatosis: Pathogenesis, diagnosis, and treatment","volume":"139","author":"Pietrangelo","year":"2010","journal-title":"Gastroenterology"},{"key":"2021122304263243300_B18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrneph.2010.139","article-title":"Iron supplementation to treat anemia in patients with chronic kidney disease","volume":"6","author":"Besarab","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"2021122304263243300_B19","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/ndt\/16.7.1416","article-title":"The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin","volume":"16","author":"Tessitore","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2021122304263243300_B20","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1093\/ndt\/gfq321","article-title":"Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents","volume":"25","author":"Tessitore","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2021122304263243300_B21","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1515\/CCLM.2005.207","article-title":"Reticulocyte hemoglobin measurement\u2014comparison of two methods in the diagnosis of iron-restricted erythropoiesis","volume":"43","author":"Thomas","year":"2005","journal-title":"Clin Chem Lab Med"},{"key":"2021122304263243300_B22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1385\/MO:23:1:23","article-title":"The diagnostic plot: A concept for identifying different states of iron deficiency and monitoring the response to epoetin therapy","volume":"23","author":"Thomas","year":"2006","journal-title":"Med Oncol"},{"key":"2021122304263243300_B23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1532\/LH96.05030","article-title":"Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma","volume":"12","author":"Katodritou","year":"2006","journal-title":"Lab Hematol"},{"key":"2021122304263243300_B24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00277-007-0258-x","article-title":"Hypochromic erythrocytes (%): A reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma","volume":"86","author":"Katodritou","year":"2007","journal-title":"Ann Hematol"},{"key":"2021122304263243300_B25","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1373\/clinchem.2004.030254","article-title":"Potential utility of Ret-Y in the diagnosis of iron-restricted erythropoiesis","volume":"50","author":"Franck","year":"2004","journal-title":"Clin Chem"},{"key":"2021122304263243300_B26","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1046\/j.1523-1755.1999.055Suppl.69061.x","article-title":"Strategies for iron supplementation: Oral versus intravenous","volume":"69","author":"Macdougall","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"2021122304263243300_B27","doi-asserted-by":"crossref","first-page":"c55","DOI":"10.1159\/000085049","article-title":"Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis","volume":"100","author":"Charytan","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"2021122304263243300_B28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bmj.299.6692.157","article-title":"Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously","volume":"299","author":"Macdougall","year":"1989","journal-title":"BMJ"},{"key":"2021122304263243300_B29","volume-title":"Experience of intravenous low molecular weight iron dextran","author":"Auerbach"},{"key":"2021122304263243300_B30","article-title":"Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: Comparison of Europe and North America","volume":"61","author":"Bailie","year":"2011","journal-title":"Arzneimittelforschung"},{"key":"2021122304263243300_B31","first-page":"688","article-title":"New intravenous iron replacement therapies","volume":"8","author":"Auerbach","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"issue":"suppl 2","key":"2021122304263243300_B32","first-page":"ii1","article-title":"Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 3","key":"2021122304263243300_B33","first-page":"S11","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","author":"KDOQI; National Kidney Foundation","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2021122304263243300_B34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0272-6386(95)90151-5","article-title":"Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation","volume":"26","author":"Fishbane","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"2021122304263243300_B35","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/ki.1996.487","article-title":"A randomized controlled study of iron supplementation in patients treated with erythropoietin","volume":"50","author":"Macdougall","year":"1996","journal-title":"Kidney Int"},{"key":"2021122304263243300_B36","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/j.ajkd.2008.05.033","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis","volume":"52","author":"Rozen-Zvi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2021122304263243300_B37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ndt\/gfi087","article-title":"Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients","volume":"21","author":"Mircescu","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2021122304263243300_B38","volume-title":"Rationale and design of a new RCT of iron therapy in anemic non-dialysis CKD patients: FIND-CKD trial [abstract SA-PO2402]","author":"Macdougall","year":"2009"},{"key":"2021122304263243300_B39","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.2004.08.119","article-title":"Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial","volume":"22","author":"Auerbach","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122304263243300_B40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1634\/theoncologist.12-2-231","article-title":"Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy","volume":"12","author":"Henry","year":"2007","journal-title":"The Oncologist"},{"key":"2021122304263243300_B41","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.leu.2404562","article-title":"Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study","volume":"21","author":"Hedenus","year":"2007","journal-title":"Leukemia"},{"key":"2021122304263243300_B42","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.2006.10.4620","article-title":"Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia","volume":"26","author":"Bastit","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122304263243300_B43","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.2007.12.2051","article-title":"Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha","volume":"26","author":"Pedrazzoli","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122304263243300_B44","doi-asserted-by":"crossref","first-page":"9109","DOI":"10.1200\/jco.2007.25.18_suppl.9109","article-title":"A phase 3 randomized controlled study comparing iron sucrose intravenously to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent therapy","volume":"25","author":"Bellet","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122304263243300_B45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ajh.21779","article-title":"Darbepoetin alfa 300 or 500 \u03bcg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia","volume":"85","author":"Auerbach","year":"2010","journal-title":"Am J Hematol"},{"key":"2021122304263243300_B46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2010.30.3644","article-title":"Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia","volume":"29","author":"Steensma","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5 suppl","key":"2021122304263243300_B47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0272-6386(03)00373-1","article-title":"Safety in iron management","volume":"41","author":"Fishbane","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2021122304263243300_B48","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1755.2003.00125.x","article-title":"High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity","volume":"64","author":"Deicher","year":"2003","journal-title":"Kidney Int"},{"key":"2021122304263243300_B49","doi-asserted-by":"crossref","first-page":"457","DOI":"10.5414\/CNP57457","article-title":"Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients","volume":"57","author":"Hoen","year":"2002","journal-title":"Clin Nephrol"},{"key":"2021122304263243300_B50","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1097\/01.ASN.0000130149.18412.56","article-title":"Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: No correlation to peroxide generation","volume":"15","author":"Scheiber-Mojdehkar","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2021122304263243300_B51","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1097\/01.ASN.0000128009.69594.BE","article-title":"Administration of parenteral iron and mortality among hemodialysis patients","volume":"15","author":"Feldman","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2021122304263243300_B52","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1681\/ASN.2005040423","article-title":"Time-dependent associations between iron and mortality in hemodialysis patients","volume":"16","author":"Kalantar-Zadeh","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 3","key":"2021122304263243300_B53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2362.2005.01529.x","article-title":"Benefits and risks of iron therapy for chronic anaemias","volume":"35","author":"Weiss","year":"2005","journal-title":"Eur J Clin Invest"},{"key":"2021122304263243300_B54","first-page":"19","article-title":"The role of iron in cancer","volume":"5","author":"Weinberg","year":"1996","journal-title":"Eur J Cancer Prev"},{"key":"2021122304263243300_B55","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/hep.1840110629","article-title":"Pathogenesis of hepatocellular carcinoma in hereditary hemochromatosis: Occurrence in noncirrhotic patients","volume":"11","author":"Kew","year":"1990","journal-title":"Hepatology"},{"key":"2021122304263243300_B56","volume-title":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Cancer- and Treatment-Related Anemia. V. 1. 2008","author":"National Comprehensive Cancer Network"},{"key":"2021122304263243300_B57","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2006.10.014","article-title":"EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update","volume":"43","author":"Bokemeyer","year":"2007","journal-title":"Eur J Cancer"},{"key":"2021122304263243300_B58","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) study","volume":"18","author":"Coyne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2021122304263243300_B59","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/ki.2010.254","article-title":"Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients","volume":"78","author":"Ford","year":"2010","journal-title":"Kidney Int"},{"key":"2021122304263243300_B60","volume-title":"FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3\/4 CKD patients [abstract SA-FC416]","author":"Besarab","year":"2010"},{"key":"2021122304263243300_B61","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1046\/j.1523-1755.1999.00436.x","article-title":"Dialysate iron therapy: Infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis","volume":"55","author":"Gupta","year":"1999","journal-title":"Kidney Int"},{"key":"2021122304263243300_B62","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2009-09-245977","article-title":"Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia","volume":"115","author":"Sasu","year":"2010","journal-title":"Blood"},{"key":"2021122304263243300_B63","volume-title":"NOX-H94, a 44-Nucleotide L-RNA Oligonucleotide Linked to 40 kDa PEG to Antagonise Hepcidin Activity Using Spiegelmers Technology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-S3-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-S3-25","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/S3\/25\/41855556\/oncolo_16_s3_25.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/S3\/25\/41855556\/oncolo_16_s3_25.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T13:39:23Z","timestamp":1640266763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/S3\/25\/6400692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,20]]},"references-count":63,"journal-issue":{"issue":"S3","published-online":{"date-parts":[[2011,2,20]]},"published-print":{"date-parts":[[2011,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-s3-25","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,8,1]]},"published":{"date-parts":[[2011,2,20]]}}}